Insider transactions

Stelios Papadopoulos

CIK 1202098 · last filed 2026-05-29

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$90.62M
Companies
7
Total Filings
113
Lifetime Open-Market Net
-$16.51M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

EXEL price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O EXELIXIS, INC.
1851 HARBOR BAY PKWY
ALAMEDA, CA 94502
Related Filers
BIOGEN INC. — 18 joint filings, latest 2022-06-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
EXEL Director 1,197,595 $69.39 $83.10M -$15.23M 38 2026-05-29
OVID Director 217,578 $2.54 $552.6K $0 3 2026-04-09
Regulus Therapeutics Inc. (RGLS) Delisted Director 0 $8.16 $0 $2.77M 34 2025-06-27
BIIB Director 27,470 $253.62 $6.97M -$5.43M 16 2022-06-17
Eucrates Biomedical Acquisition Corp. (EUCRU) Delisted Director 2,619,906 $10.02 $26.25M $0 1 2020-11-27
BG Medicine, Inc. (BGMD) Delisted Director 296,928 — — $1.02M 7 2013-06-14
ANADYS PHARMACEUTICALS INC (ANDS) Delisted Director 814,206 — — $369.5K 10 2011-05-27

Recent Filings · Page 6 of 12

113 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-06-14 BIIB Grant (A) +1,450 $0 EDGAR
2018-06-05 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2018-05-24 EXEL Grant (A) +7,937 $0 EDGAR
2018-05-21 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) — $0 EDGAR
2018-05-07 EXEL Mixed — -$157.3K EDGAR
2018-03-02 EXEL Mixed — -$241.2K EDGAR
2017-12-06 Regulus Therapeutics Inc. (RGLS) Delisted Grant (A) +96,629 $86.0K EDGAR
2017-09-22 EXEL Sell (S) −10,000 -$254.0K EDGAR
2017-09-20 EXEL Sell (S) −200,000 -$5.54M EDGAR
2017-07-25 Regulus Therapeutics Inc. (RGLS) Delisted Buy (P) +1,000,000 $910.0K EDGAR
Showing 51–60 of 113
Page 6 of 12
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.